section name header

Pronunciation ⬇

li-NEZ-o-lid

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Pharmacologic Classification: oxazolidinones

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits bacterial protein synthesis at the level of the 23S ribosome of the 50S subunit.
Therapeutic effects:
  • Bactericidal action against streptococci; bacteriostatic action against enterococci and staphylococci.

Spectrum:

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly and extensively (100%) absorbed following oral administration. IV administration results in complete bioavailability.

Distribution: Readily distributes to well-perfused tissues.

Metabolism/Excretion: 65% metabolized, mostly by the liver; 30% excreted unchanged by the kidneys.

Half-Life: 6.4 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
POrapid1–2 hr12 hr
IVrapidend of infusion12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: headache, insomnia

Derm: toxic epidermal necrolysis

EENT: teeth discoloration, tongue discoloration

Endo: hypoglycemia, syndrome of inappropriate diuretic hormone (SIADH) secretion

F and E: hyponatremia, lactic acidosis

GI: ↑liver enzymes, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), diarrhea, nausea, vomiting

Hemat: anemia, leukopenia, thrombocytopenia

MS: RHABDOMYOLYSIS

Neuro: dysgeusia, optic neuropathy, peripheral neuropathy

Misc: SEROTONIN SYNDROME

Interactions ⬆ ⬇

Drug-drug:

Drug-Food:

Route/Dosage ⬆ ⬇

Vancomycin-Resistant Enterococcus faecium Infections

Pneumonia or Complicated Skin/Skin Structure Infections

Uncomplicated Skin/Skin Structure Infections

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Zyvox

Canadian Brand Names ⬆ ⬇

Zyvoxam

Code ⬆

NDC Code